Search

Displaying results 5991 - 6000 of 10000 in total
  1. Drug

    TY027

    go.drugbank.com/drugs/DB16500
    Investigational

  2. Drug

    Sonepcizumab

    go.drugbank.com/drugs/DB06305
    Investigational

    Upon administration, sonepcizumab binds S1P, which may result in the inhibition of tumor angiogenesis. … S1P is the extracellular ligand for the G protein-coupled lysophospholipid receptor EDG-1 (endothelial differentiation gene-1).

  3. Drug

    Epothilone D

    go.drugbank.com/drugs/DB01873
    Investigational

  4. Drug

    Palm oil

    go.drugbank.com/drugs/DB14377
    Investigational

    Palm oil is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.

    Synonyms: African Oil Palm Fruit Oil, Oil PalmProducts: Oil
  5. Drug

    Aluminum zirconium tetrachlorohydrex gly

    go.drugbank.com/drugs/DB11149
    ApprovedWithdrawn

    Aluminum zirconium tetrachlorohydrex gly is a common active ingredient in personal care products as an antiperspirant agent. … Its main mechanism of action is through blocking the pores via formation of polymer complex and preventing sweat from leaving the body.

  6. Drug

    Rutin

    go.drugbank.com/drugs/DB01698
    ApprovedInvestigational

    A flavonol glycoside found in many plants, including buckwheat; tobacco; forsythia; hydrangea; viola, etc. It has been used therapeutically to decrease capillary fragility.

    Synonyms: 3-[[6-O-(6-Deoxy-alpha-L-mannopyranosyl)-beta-D-glucopyranosyl]oxy]-2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-4H-1-benzopyran-4-one
  7. Drug

    Nomegestrol acetate

    go.drugbank.com/drugs/DB13981
    Approved

    Nomegestrol acetate, also known as NOMAC, is a progestin used in oral contraceptives, menopausal hormone therapy, and for the treatment of gynecological disorders.

  8. Drug

    Caldaret

    go.drugbank.com/drugs/DB06231
    Investigational

  9. Drug

    Osanetant

    go.drugbank.com/drugs/DB04872
    Investigational

    In a review of its R&D portfolio, the company announced in August 2005 that it would cease any further development of osanetant. … Developed by Sanofi-Aventis (formerly Sanofi-Synthelabo), osanetant (SR-142801) is an NK3 receptor antagonist which was under development for the treatment of schizophrenia and other Central Nervous System

  10. Drug

    Gantenerumab

    go.drugbank.com/drugs/DB12034
    Investigational

    Alzheimer's disease (AD) is the most common cause of dementia in elderly patients, with classical histopathological hallmarks including extracellular amyloid-beta (Aβ) plaques and intraneuronal neurofibrillary … [A244705, A244710, A244745] Gantenerumab is a fully human IgG1κ monoclonal antibody derived from the MorphoSys HuCAL®-Fab1 phage display library and subsequently optimized by _in vitro_ CDR cassette